Liisa Petäjä1, Helge Røsjø2, Leena Mildh3, Raili Suojaranta-Ylinen4, Kirsi-Maija Kaukonen3, Janne J Jokinen5, Markku Salmenperä4, Tor-Arne Hagve6, Torbjørn Omland2, Ville Pettilä3. 1. Division of Anaesthesiology, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland liisa.petaja@hus.fi. 2. Division of Medicine, Akershus University Hospital, Lørenskog, Norway Institute of Clinical Medicine, K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, University of Oslo, Oslo, Norway. 3. Division of Intensive Care Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 4. Division of Anaesthesiology, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 5. Department of Thoracic and Vascular Surgery, Päijät-Häme Central Hospital, Lahti, Finland. 6. Division of Diagnostics and Technology, Akershus University Hospital, Lørenskog, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
OBJECTIVES: Plasma troponins, measured by fourth-generation assays, are associated with increased mortality and morbidity after cardiac surgery. They also offer predictive information in addition to EuroSCORE, a widely used risk model after cardiac surgery. However, preoperatively measured troponin has provided no additional information to postoperative values. Whether these facts hold true also for the high-sensitivity fifth-generation troponin assay and the better calibrated risk model, EuroSCORE II, is unknown. We hypothesized that preoperative and/or postoperative high-sensitivity troponin T (hs-TnT) would increase the predictive value of EuroSCORE II. METHODS: Consecutive coronary artery bypass grafting (CABG) and other cardiac surgical patients were prospectively enrolled in a university hospital. Plasma samples and EuroSCORE II variables were collected. The primary and secondary end-points were 180-day mortality and any major adverse event within 30 days, and 961-day mortality. The data were analysed by Kaplan-Meier survival curves, regression analyses, receiver operator characteristic curves and decision curve analysis. RESULTS: Mortality rates in 180 days were 3.5% (15/428) in CABG and 6.4% (14/220) in other cardiac surgical patients. Survival curves differed only in patients with not only high postoperative hs-TnT value (>500 ng/l), but also high preoperative hs-TnT value (>14 ng/l), compared with patients with both hs-TnT values low. Adding hs-TnT to EuroSCORE II improved the prediction of 180-day mortality in other cardiac surgical patients (maximum net benefit of 1.5%), but not in CABG patients. Regarding major adverse events, adding hs-TnT to EuroSCORE II improved the prediction in both CABG patients and other cardiac surgical patients (maximum net benefits of 3 and 7%). CONCLUSIONS: Elevated postoperative hs-TnT was predictive of mortality only when combined with elevated preoperative hs-TnT. Hs-TnT measurements added information to the EuroSCORE II regarding major adverse events in all cardiac surgical patients and regarding 180-day mortality in non-CABG patients.
OBJECTIVES: Plasma troponins, measured by fourth-generation assays, are associated with increased mortality and morbidity after cardiac surgery. They also offer predictive information in addition to EuroSCORE, a widely used risk model after cardiac surgery. However, preoperatively measured troponin has provided no additional information to postoperative values. Whether these facts hold true also for the high-sensitivity fifth-generation troponin assay and the better calibrated risk model, EuroSCORE II, is unknown. We hypothesized that preoperative and/or postoperative high-sensitivity troponin T (hs-TnT) would increase the predictive value of EuroSCORE II. METHODS: Consecutive coronary artery bypass grafting (CABG) and other cardiac surgical patients were prospectively enrolled in a university hospital. Plasma samples and EuroSCORE II variables were collected. The primary and secondary end-points were 180-day mortality and any major adverse event within 30 days, and 961-day mortality. The data were analysed by Kaplan-Meier survival curves, regression analyses, receiver operator characteristic curves and decision curve analysis. RESULTS: Mortality rates in 180 days were 3.5% (15/428) in CABG and 6.4% (14/220) in other cardiac surgical patients. Survival curves differed only in patients with not only high postoperative hs-TnT value (>500 ng/l), but also high preoperative hs-TnT value (>14 ng/l), compared with patients with both hs-TnT values low. Adding hs-TnT to EuroSCORE II improved the prediction of 180-day mortality in other cardiac surgical patients (maximum net benefit of 1.5%), but not in CABG patients. Regarding major adverse events, adding hs-TnT to EuroSCORE II improved the prediction in both CABG patients and other cardiac surgical patients (maximum net benefits of 3 and 7%). CONCLUSIONS: Elevated postoperative hs-TnT was predictive of mortality only when combined with elevated preoperative hs-TnT. Hs-TnT measurements added information to the EuroSCORE II regarding major adverse events in all cardiac surgical patients and regarding 180-day mortality in non-CABG patients.
Authors: Samer A M Nashef; François Roques; Linda D Sharples; Johan Nilsson; Christopher Smith; Antony R Goldstone; Ulf Lockowandt Journal: Eur J Cardiothorac Surg Date: 2012-02-29 Impact factor: 4.191
Authors: Sara Nisula; Kirsi-Maija Kaukonen; Suvi T Vaara; Anna-Maija Korhonen; Meri Poukkanen; Sari Karlsson; Mikko Haapio; Outi Inkinen; Ilkka Parviainen; Raili Suojaranta-Ylinen; Jouko J Laurila; Jyrki Tenhunen; Matti Reinikainen; Tero Ala-Kokko; Esko Ruokonen; Anne Kuitunen; Ville Pettilä Journal: Intensive Care Med Date: 2013-01-05 Impact factor: 17.440
Authors: William J Lyon; Robert A Baker; Marie J Andrew; Rosy Tirimacco; Graham H White; John L Knight Journal: ANZ J Surg Date: 2003 Jan-Feb Impact factor: 1.872
Authors: Giovanna A L Lurati Buse; Daniel Bolliger; Esther Seeberger; Jorge Kasper; Martin Grapow; Michael T Koller; Manfred D Seeberger; Miodrag Filipovic Journal: Circulation Date: 2014-08-06 Impact factor: 29.690
Authors: Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-10-22 Impact factor: 24.094
Authors: Abhiram Prasad; Charanjit S Rihal; Ryan J Lennon; Mandeep Singh; Allan S Jaffe; David R Holmes Journal: Circ Cardiovasc Interv Date: 2008-08 Impact factor: 6.546
Authors: Jared P Beller; Robert B Hawkins; J Hunter Mehaffey; Damien J LaPar; Irving L Kron; Leora T Yarboro; Gorav Ailawadi; Ravi K Ghanta Journal: Ann Thorac Surg Date: 2018-03-08 Impact factor: 4.330
Authors: Eero Pesonen; Hanna Vlasov; Raili Suojaranta; Seppo Hiippala; Alexey Schramko; Erika Wilkman; Tiina Eränen; Kaapo Arvonen; Maxim Mazanikov; Ulla-Stina Salminen; Mihkel Meinberg; Tommi Vähäsilta; Liisa Petäjä; Peter Raivio; Tatu Juvonen; Ville Pettilä Journal: JAMA Date: 2022-07-19 Impact factor: 157.335
Authors: Brigitta Gahl; Volkhard Göber; Ayodele Odutayo; Hendrik T Tevaearai Stahel; Bruno R da Costa; Stephan M Jakob; G Martin Fiedler; Olivia Chan; Thierry P Carrel; Peter Jüni Journal: J Am Heart Assoc Date: 2018-02-27 Impact factor: 5.501